CalciMedica, Inc. Common Stock Asset Resilience Ratio
CalciMedica, Inc. Common Stock asset resilience ratio. CalciMedica, Inc. Common Stock (CALC) has an Asset Resilience Ratio of 11.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CALC defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CalciMedica, Inc. Common Stock (2019–2025)
Asset resilience ratio of CalciMedica, Inc. Common Stock from 2019 to 2025. This chart shows how CalciMedica, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read CalciMedica, Inc. Common Stock (CALC) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CalciMedica, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CALC total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 11.01% |
| Total Liquid Assets | $1.50 Million | 11.01% |
Asset Resilience Insights
- Moderate Liquidity: CalciMedica, Inc. Common Stock has 11.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
CalciMedica, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CalciMedica, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
CalciMedica, Inc. Common Stock Asset Resilience Ratio by Year (2019–2025)
CalciMedica, Inc. Common Stock asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for CalciMedica, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.01% | $1.50 Million | $13.59 Million | -43.22pp |
| 2024-12-31 | 54.23% | $10.73 Million | $19.79 Million | +7.38pp |
| 2023-12-31 | 46.84% | $5.71 Million | $12.19 Million | -25.97pp |
| 2021-12-31 | 72.81% | $50.31 Million | $69.09 Million | +12.29pp |
| 2020-12-31 | 60.53% | $61.62 Million | $101.79 Million | +11.13pp |
| 2019-12-31 | 49.40% | $20.09 Million | $40.66 Million | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more